Pharmacogenetics of warfarin dosing in patients of African and European ancestry [0.03%]
华法林在非洲和欧洲血统患者中的用药剂量的药物基因组学研究
Aditi Shendre,Chrisly Dillon,Nita A Limdi
Aditi Shendre
Despite the introduction of direct acting oral anticoagulants, warfarin remains the most commonly prescribed oral anticoagulant. However, warfarin therapy is plagued by the large inter- and intrapatient variability. The variability in dosin...
Impact of UGT2B7 and ABCC2 genetic polymorphisms on mycophenolic acid metabolism in Chinese renal transplant recipients [0.03%]
UGT2B7和ABCC2基因多态性对中国肾移植受者霉酚酸代谢的影响
Li-Qing Li,Di-Na Chen,Chuan-Jiang Li et al.
Li-Qing Li et al.
Aim: To evaluate genetic variants affecting mycophenolic acid (MPA) metabolism in Chinese renal transplant recipients. Methods: Total 1...
Pharmacogenomics and implementation of precision therapeutics in the neonatal ICU: a new frontier? [0.03%]
新生儿ICU中的药物基因组学和精准治疗的实施：一个新的前沿吗？
Tamorah Lewis,J Steven Leeder
Tamorah Lewis
How to make P-glycoprotein (ABCB1, MDR1) harbor mutations and measure its expression and activity in cell cultures? [0.03%]
如何在细胞培养中引入P-糖蛋白（ABCB1、MDR1）的突变并测量其表达和活性？
Pablo Zubiaur,Miriam Saiz-Rodríguez,Dora Koller et al.
Pablo Zubiaur et al.
Several polymorphisms have been identified in ABCB1, the gene encoding for the P-glycoprotein. This transporter alters the pharmacokinetics or effectiveness of drugs by excreting them from cells where it is expressed (e.g., blood-brain barr...
Precision HIV care: responding to old questions and meeting new challenges [0.03%]
精准的HIV治疗：回应老问题，迎接新挑战
Todd Hulgan,Chandravanu Dash,David W Haas et al.
Todd Hulgan et al.
RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms [0.03%]
他汀类药物相关肌肉症状的RYR1和CACNA1S基因变异筛查研究
Paul J Isackson,Jianxin Wang,Mohammad Zia et al.
Paul J Isackson et al.
Aim: To examine the genetic differences between subjects with statin-associated muscle symptoms and statin-tolerant controls. Materials & methods: ...
Louis-Philippe Lemieux Perreault,Nabil Zaïd,Michel Cameron et al.
Louis-Philippe Lemieux Perreault et al.
Aim: We have evaluated the pharmacogenetic content of commercial human genome-wide genotyping arrays, as it is a critical determinant to enabling pharmacogenomic discoveries. ...
Reducing anthracycline-induced cardiotoxicity through pharmacogenetics [0.03%]
利用药物基因组学减少蒽环类药物引起的心脏毒性
Erika Scott,Jafar S Hasbullah,Colin Jd Ross et al.
Erika Scott et al.
Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study [0.03%]
药物基因型与重度抑郁障碍和/或双相情感障碍的治疗：一项回顾性横断面研究
Theresa R Tonozzi,Glenn D Braunstein,Anja Kammesheidt et al.
Theresa R Tonozzi et al.
Aim: To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications. ...
Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients [0.03%]
年龄和Vkorc1、Cyp2C9及Cyp3a4基因多态性对儿科患者苯丙香豆素剂量的影响
Hedy Maagdenberg,Marc B Bierings,C Heleen van Ommen et al.
Hedy Maagdenberg et al.
Aim: To study the effects of clinical and genetic factors on the phenprocoumon dose requirement in pediatric patients and to develop a dosing algorithm. M...